Snell & Wilmer Represents Biotech Nexturn Bio, Inc. in its Majority Stake Investment in RosVivo Therapeutics Inc.

SAN DIEGO – Snell & Wilmer has been engaged by Nexturn Bio, Inc. (Nexturn), a South Korean biotech company as representation in its majority stake investment in RosVivo Therapeutics Inc., a Nevada-based new drug development corporation. 

Nexturn stated in a recent press release that it “decided to invest in the development of a new drug pipeline for diabetes treatment using miRNA” which was recently developed by RosVivo Therapeutic Inc. that “has significantly reduced side effects of the current diabetes drugs on the market” and can “maximize effectiveness by reducing drug and insulin resistance from long-term use.” 

Bardia Moayedi led the Snell & Wilmer team advising Nexturn in the deal. The team includes Charles Gianelloni (commercial litigation), Brett Johnson (government relations) and Sarah Hibbard (corporate and securities).

Snell & Wilmer’s life science and medical technology lawyers currently represent a diverse client base from the bioscience, pharmaceutical (both prescription and OTC), medical device and healthcare industries, ranging from large publicly-traded organizations to early and mid-stage start-up companies. Clients include manufacturers, distributors, inventors, researchers, venture capitalists, angel investors, engineers, product designers and vendors, in their intellectual property, transactional, litigation and various other legal matters.